In this episode, co-host Andreas Seas interviews Jon Nelson who shares his experience with deep brain stimulation for treatment-resistant depression. Listen as he shares about the hope this treatment approach gave him and how DBS has transformed his life. This treatment remains investigational, but with the studies underway that can help patients like Jon, we can start to understand the profound impact it can have.
All content for ASSFN Podcast is the property of ASSFN and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, co-host Andreas Seas interviews Jon Nelson who shares his experience with deep brain stimulation for treatment-resistant depression. Listen as he shares about the hope this treatment approach gave him and how DBS has transformed his life. This treatment remains investigational, but with the studies underway that can help patients like Jon, we can start to understand the profound impact it can have.
STN vs GPI DBS for Parkinson's with Dr. Kelly Foote
ASSFN Podcast
34 minutes
3 years ago
STN vs GPI DBS for Parkinson's with Dr. Kelly Foote
In this podcast episode, host Danika Paulo and featured guest speaker, Dr. Kelly Foote, Professor of Neurosurgery at the University of Florida, discuss the two most common deep brain stimulation targets for Parkinson's Disease - subthalamic nucleus (STN) and globus pallidus internus (GPI). Our conversation covers anatomic and neurophysiologic differences between the two targets, clinical considerations of when and why to choose one target over the other, bilateral vs unilateral implants, diff...
ASSFN Podcast
In this episode, co-host Andreas Seas interviews Jon Nelson who shares his experience with deep brain stimulation for treatment-resistant depression. Listen as he shares about the hope this treatment approach gave him and how DBS has transformed his life. This treatment remains investigational, but with the studies underway that can help patients like Jon, we can start to understand the profound impact it can have.
